• Imidazoles Target AdhE in Cryptosporidium parvum: Screening

  2026-06-17

  This study identifies potent lower-micromolar inhibitors of the bifunctional aldehyde/alcohol dehydrogenase (AdhE) enzyme in Cryptosporidium parvum, highlighting antifungal imidazoles as promising leads. These findings provide a mechanistic foundation for anti-cryptosporidial drug discovery and inform future screening strategies for neglected parasitic diseases.

• Live-Dead Cell Staining Kit: Precision Viability for Biomate

  2026-06-17

  Explore how the Live-Dead Cell Staining Kit empowers advanced cell viability assays with Calcein-AM Propidium Iodide staining. This article uniquely connects viability analytics to biomaterial development, unveiling practical insights for researchers.

• Precision Cell Surface Profiling: Biotin-XX Tyramide in Tran

  2026-06-16

  This thought-leadership article examines the mechanistic foundations and strategic applications of Biotin-XX Tyramide Reagent for advancing cell surface proteomics. We integrate recent protocol innovations, competitive benchmarking, and translational guidance, establishing APExBIO’s tool as a gold standard for membrane-impermeant proximity labeling and amplified signal detection in immunohistochemistry and spatial proteomics.

• Deferasirox: Oral Iron Chelator for Advanced Cancer Models

  2026-06-16

  Deferasirox stands out not only as an oral iron chelator for iron overload, but as a transformative tool for targeting iron metabolism and modulating ferroptosis in cancer research. This guide details how to integrate Deferasirox into experimental workflows, leverage new mechanistic insights, and troubleshoot common pitfalls with confidence.

• MVC Triggers RhoA/ROCK1 Pathway to Disrupt Canine Tight Junc

  2026-06-15

  This study reveals that the Minute Virus of Canines (MVC) activates the RhoA/ROCK1/MLC2 signaling pathway, causing tight junction dissociation and exposing Occludin, which facilitates viral entry. The findings provide a mechanistic basis for targeting RhoA-mediated signaling as a potential anti-viral strategy in canine parvovirus research.

• Tofacitinib (CP-690550) for Immune Cell Modulation Workflows

  2026-06-15

  Tofacitinib (CP-690550) enables precise cytokine signaling blockade and uniquely repairs mitochondrial dysfunction in RA macrophage models unresponsive to other therapies. This article translates the latest mechanistic insights into actionable protocols, troubleshooting strategies, and comparative advantages for advanced immune modulation research.

• Targeting CYP2B6 Regulation in Glioblastoma via Dominant-Neg

  2026-06-14

  This study demonstrates that CYP2B6, a key drug-metabolizing enzyme, is transcriptionally regulated by activating transcription factor 5 (ATF5) in glioblastoma cells. By introducing a cell-penetrating dominant-negative ATF5 peptide, researchers achieved effective downregulation of CYP2B6, highlighting a potential avenue for improving personalized therapy and drug dosing in glioblastoma.

• RCN2 Drives ESCC Metastasis and Chemoresistance via PI3K-AKT

  2026-06-13

  This study identifies reticulocalbin 2 (RCN2) as a key facilitator of metastasis and cisplatin resistance in esophageal squamous cell carcinoma (ESCC) through UBR5-mediated degradation of PPP2CA and subsequent activation of the PI3K-AKT signaling pathway. The findings highlight RCN2 as a promising therapeutic target and provide mechanistic insights into ESCC progression and drug resistance.

• FLOT1–FOSL2–EphA2 Axis Regulates Microglial Polarization in

  2026-06-12

  This study uncovers how interaction between FLOT1 and FOSL2 upregulates EphA2, activating the p38/MAPK pathway and promoting pro-inflammatory microglial polarization in Alzheimer's disease. The findings provide mechanistic insight into neuroinflammation and highlight a potential therapeutic target for modulating AD progression.

• CAF-Derived Lactate Drives Oxaliplatin Resistance in Colorec

  2026-06-12

  This study reveals how lactate from cancer-associated fibroblasts fosters oxaliplatin resistance in colorectal cancer by enhancing ANTXR1 lactylation and stemness pathways. These insights clarify the tumor-stroma interplay in chemoresistance and provide a mechanistic basis for targeting lactate-mediated signaling to improve therapeutic efficacy.

• RIPA Lysis Buffer (Strong): Optimizing Protein Extraction Wo

  2026-06-11

  RIPA Lysis Buffer (Strong) empowers researchers to achieve high-yield, low-degradation protein extraction from animal tissues and cultured cells, critical for advanced immunoassays and pathway analysis. This guide details workflow enhancements, experimental troubleshooting, and practical insights inspired by recent glioma research.

• NSP2-MYB Module Coordinates Flavonoid Biosynthesis and Symbi

  2026-06-11

  Gao et al. delineate a molecular module, comprising NSP2 and MYB40, that integrates symbiotic signaling and flavonoid biosynthesis to optimize legume nodulation and mycorrhizal interactions under nutrient stress. These findings clarify how metabolic and symbiotic pathways are transcriptionally coordinated, offering new insights for plant-microbe research.

• Experimental Use of Angiotensin II: Protocols and Pitfalls

  2026-06-10

  Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) is routinely used to model hypertension, cardiovascular remodeling, and vascular smooth muscle cell hypertrophy in both in vitro and in vivo studies. This reagent is best suited for controlled research workflows that require precise control of dosing, solubility, and storage. It is not intended for diagnostic or clinical use, and long-term solution storage or use with ethanol as a solvent should be avoided.

• Palomid 529: Applied PI3K/Akt/mTOR Inhibition in Cancer Mode

  2026-06-10

  Palomid 529 (P529) brings dual mTORC1/mTORC2 inhibition to advanced cancer and resistance studies, with potent anti-angiogenic and radiotherapy-enhancing effects. This guide delivers protocol optimizations, troubleshooting insights, and data-driven use cases for translational oncology workflows.

• RCN2 Drives ESCC Metastasis and Cisplatin Resistance via PI3

  2026-06-09

  This study uncovers the mechanism by which RCN2 promotes metastasis and cisplatin resistance in esophageal squamous cell carcinoma (ESCC). By facilitating UBR5-mediated degradation of PPP2CA, RCN2 sustains PI3K-AKT pathway activation, highlighting a new therapeutic target for aggressive, treatment-resistant ESCC.

16714 records 1/1115 page Next 12345 下5页 Last page